# MBX Biosciences, Inc.: overview MBX · Nasdaq · CIK 1776111 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mbx.md) · [Financials](/companies/mbx/financials.md) · [Filings](/companies/mbx/filings.md) · [Insiders](/companies/mbx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.78)](/filings/0001193125-25-268148.md) | not reported | [(0.71)](/filings/0001193125-26-210593.md) | [(0.58)](/filings/0001193125-26-336849.md) | [(0.63)](/filings/0001193125-25-268148.md) | not reported | [(0.50)](/filings/0001193125-26-210593.md) | [(0.78)](/filings/0001193125-26-336849.md) | | Free cash flow | $m | [(14.7) d](/filings/0001193125-25-268148.md) | [(16.1) d](/filings/0001193125-26-103121.md) | [(22.7)](/filings/0001193125-26-210593.md) | [(18.1) d](/filings/0001193125-26-336849.md) | [(21.9) d](/filings/0001193125-25-268148.md) | [(19.1) d](/filings/0001193125-26-103121.md) | [(20.6)](/filings/0001193125-26-210593.md) | [(23.5) d](/filings/0001193125-26-336849.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | | Diluted EPS | $ per share | [(31.96)](/filings/0000950170-25-039838.md) | [(5.82)](/filings/0001193125-26-103121.md) | [(2.38)](/filings/0001193125-26-103121.md) | | Free cash flow | $m | [(32.1)](/filings/0000950170-25-039838.md) | [(55.6)](/filings/0001193125-26-103121.md) | [(81.9)](/filings/0001193125-26-103121.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mbx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Frazier Life Sciences Management, L.P.](/funds/1892134.md) | 2026-06-30 | $367.2m | 6,652,013 | | Unchanged | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $293.8m | 5,322,885 | | Added +2,386,201 | | [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $274.8m | 4,977,523 | | Added +1,785,699 | | [NEA Management Company, LLC](/funds/1512848.md) | 2026-06-30 | $199.5m | 3,614,486 | | Unchanged | | [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $189.3m | 3,428,736 | | Reduced −209,151 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $183.5m | 3,323,672 | | Added +382,266 | | [Paradigm Biocapital Advisors LP](/funds/1855655.md) | 2026-06-30 | $138.4m | 2,508,015 | | New +2,508,015 | | [NVP ASSOCIATES, LLC](/funds/1545692.md) | 2026-06-30 | $117.9m | 2,136,335 | | Unchanged | | [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $95.6m | 1,732,569 | | Reduced −1,025,000 | | [Polar Capital Holdings Plc](/funds/1837309.md) | 2026-06-30 | $88.8m | 1,608,514 | | Reduced −13,672 | ## Recent filings [All 226 filings](/companies/mbx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 12:11 ET | [8-K](/filings/0001193125-26-428367.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-428367 | | 2026-08-27 | 12:34 ET | [8-K](/filings/0001193125-26-369674.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-369674 | | 2026-08-10 | 21:35 ET | [SCHEDULE 13D/A](/filings/0001231919-26-000851.md) | Ownership report, active investor, amended | 0001231919-26-000851 | | 2026-08-10 | 20:44 ET | [SCHEDULE 13D/A](/filings/0000947871-26-000776.md) | Ownership report, active investor, amended | 0000947871-26-000776 | | 2026-08-06 | 12:06 ET | [10-Q](/filings/0001193125-26-336849.md) | Quarterly report, period 2026-06-30 | 0001193125-26-336849 | | 2026-08-06 | 12:03 ET | [8-K](/filings/0001193125-26-336841.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-336841 | | 2026-07-13 | 20:46 ET | [8-K](/filings/0001193125-26-302098.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-302098 | | 2026-06-12 | 11:05 ET | [8-K](/filings/0001193125-26-268477.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-268477 | | 2026-06-05 | 11:52 ET | [8-K](/filings/0001193125-26-258417.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001193125-26-258417 | | 2026-05-11 | 11:04 ET | [8-K](/filings/0001193125-26-215676.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-215676 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-103121.md), filed Mar 12, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1776111 - Tickers: MBX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.